Nanodigmbio
Singapore, Singapore· Est.
A Singapore‑based NGS diagnostics platform delivering ultra‑sensitive, rapid targeted sequencing solutions for oncology and infectious disease.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A Singapore‑based NGS diagnostics platform delivering ultra‑sensitive, rapid targeted sequencing solutions for oncology and infectious disease.
OncologyInfectious DiseasesGenetic DisordersHematologyImmunology
Technology Platform
Targeted NGS using ultra‑sensitive hybrid‑capture probes, molecular identifiers for error correction, and rapid library preparation compatible with Illumina and MGI platforms.
Opportunities
Expansion into global clinical‑lab markets and addition of liquid‑biopsy and immuno‑oncology panels could drive significant revenue growth.
Risk Factors
Regulatory approval timelines for IVD kits and intense competition from established NGS reagent manufacturers pose key risks.
Competitive Landscape
Nanodigmbio competes with Illumina, BGI, Twist Bioscience and Roche Diagnostics, differentiating through ultra‑sensitive probe chemistry and integrated workflow automation.